ABSTRACT
At present, the treatment of relapsed/refractory acute myeloid leukemia (AML) is still challenging, and there is no standard treatment for relapsed/refractory AML patients. Current research believes that participating in clinical trials involving small molecule targeted therapy, immunotherapy and epigenetic therapy may be the best choice, but the efficacy and toxicity of clinical trials have not been widely evaluated, and the long-term survival of patients is not clear, so the prognosis of relapsed/refractory AML is still very poor. The future direction of research will focus on novel, effective and targeted treatment combinations, and low toxicity, personalized and accurate treatment strategies. This article reviews the latest progress in targeted therapy for relapsed/refractory AML.